CAR-T

CAR T-cell therapies in treating lymphoma: Pros and consCatherine Bollard, MD, discusses the success rate of CAR T-cell treatments, remaining obstacles, and top payer considerations.
Three things health execs need to know about CAR T-cell therapyHere’s your quick guide to understanding how CAR T-cell therapy could affect patients and payers.
What oncologists say about new cancer treatment optionsA new report from Cardinal Health Specialty Solutions gives behind-the-scenes perspectives from oncologists about CAR-T cell therapies, biosimilars and AML therapies (or genomic medicines)
Ovarian cancer could be next application for CAR T-cell therapyWhile CAR T-cell therapy has been proven to work for liquid—or blood—cancers, the challenge has been to apply this technology to solid tumors.
Patient experience with immunotherapy: 4 things health execs need to knowCAR T-cell therapies and other immunotherapy give this oncologist’s cancer patients hope for a better quality of life.
Four oncology treatment advances to watch
Four oncology treatment advances to watchExperts say a cancer care revolution is here. Here’s a closer look at some advancements in cancer treatments to watch.
Ten ways multiple myeloma treatment is changingAs multiple myeloma treatment improvements continue, it’s important for managed care executives to get out in front of these 10 changes on the horizon.
Tisagenlecleucel (Kymriah) for Acute Lymphoblastic Leukemia
Tisagenlecleucel (Kymriah) for Acute Lymphoblastic LeukemiaA new era of treatment has arrived—here’s what you need to know.
Payers struggle to keep up with high rate of FDA drug approvalsFDA incentives have hastened the development of “orphan drugs” for rare diseases, but some worry that regulators are not always demanding clear evidence for drug efficacy.
Game-changing gene therapies present cost problems for health execsCAR-T therapies have high price tags so it’s important to understand your patient population and budget impact.